AbCellera Biologics financials
$14.82+6.47%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.0M | $8.3M | $44.9M | $9.0M | $17.1M | $4.2M | $5.0M | $6.5M | $7.3M | $10.0M | $9.2M | $6.6M |
| Gross profit | $4.0M | $8.3M | $44.9M | $9.0M | $17.1M | $4.2M | $5.0M | $6.5M | $7.3M | $10.0M | $9.2M | $6.6M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$62.8M | -$57.5M | -$28.6M | -$76.3M | -$49.6M | -$62.7M | -$72.8M | -$93.7M | -$93.5M | -$54.9M | -$66.1M | -$54.9M |
| Net income | -$55.4M | -$43.2M | -$8.9M | -$57.1M | -$34.7M | -$45.6M | -$34.2M | -$51.1M | -$36.9M | -$40.6M | -$47.1M | -$28.6M |
| Net margin | −1368.6% | −519.1% | −19.9% | −637.8% | −203.3% | −1077.2% | −677.4% | −785.4% | −504.3% | −408.0% | −513.7% | −433.6% |
| Diluted EPS | $-0.18 | $-0.14 | $-0.03 | $-0.19 | $-0.12 | $-0.15 | $-0.12 | $-0.17 | $-0.13 | $-0.14 | $-0.16 | $-0.10 |
| EBITDA | -$57.6M | -$50.7M | -$26.2M | -$71.0M | -$46.0M | -$57.3M | -$138.5M | -$56.7M | -$56.9M | -$50.0M | -$66.1M | -$49.2M |
| Operating cash flow | $25.9M | -$33.5M | -$34.7M | -$52.6M | -$32.4M | -$11.6M | -$8.0M | -$28.9M | -$30.0M | -$41.7M | -$19.6M | -$106.0K |
| Free cash flow | $23.8M | -$37.4M | -$44.6M | -$61.5M | -$45.8M | -$22.2M | -$23.6M | -$47.4M | -$50.1M | -$65.8M | -$34.0M | -$20.4M |
| Diluted shares | 305.6M | 303.1M | 299.8M | 298.9M | 298.5M | 297.7M | 295.5M | 294.9M | 294.2M | 292.7M | 290.5M | 289.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $120.1M | $77.1M | $128.5M | $83.2M | $92.4M | $159.3M |
| Short-term investments | $420.0M | $427.7M | $405.3M | $412.5M | $460.6M | $446.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.31B | $1.31B | $1.36B | $1.36B | $1.40B | $1.34B |
| Total liabilities | $411.6M | $369.0M | $390.0M | $392.0M | $395.0M | $321.2M |
| Shareholders' equity | $896.0M | $938.1M | $966.9M | $964.0M | $1.01B | $1.02B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology